UNSPSC 51393403: Etofylline

This classification denotes a phosphodiesterase inhibitor with the molecular formula C9H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L164909TBI, chemically known as 3,7-dihydro-7-(2-hydroxyethyl)-1,3-dimethyl-1h-purine-2,6-dione (9ci) but generally known as etofylline, which bears US NIH Compound Identifier 1892. European Medicines Agency schedules Etofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07324MIG.

UNSPSC 51393403 Etofylline is a Commodity code covering pharmaceutical active ingredients and finished pharmaceutical products, but the recent state and local opportunities tagged to this code show little direct procurement activity for etofylline itself. Instead, the two most recent solicitations tagged to this code involve naloxone (an opioid antagonist) and pharmacy benefit program management, neither of which are etofylline products. The mismatch suggests either tagging inconsistency in the source data or that state and local procurement offices are using this code as a catchall for pharmaceutical procurement despite its narrow nominal scope. If etofylline procurement does occur under this code, it would typically support municipal, county, or state health departments purchasing pharmaceutical inputs for in-house manufacturing, compounding, or medical supplies; however, the recent opportunities provide no concrete evidence of such activity.

Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with e-Verify compliance and E&O insurance required. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) seeking vendor capabilities for a direct-to-manufacturer prescription program to bypass traditional pharmacy benefit managers and group purchasing organizations. Neither opportunity is materially related to etofylline procurement. Geographic coverage is limited to Florida and Texas based on these two records. Given the absence of etofylline-specific solicitations in the recent-opportunities block, this code shows little actionable signal for vendors targeting pharmaceutical product procurement under its stated commodity definition at this time.